TRA	TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 C. 1.97(b) or 1.97(c))  Docket No. RLL-254US						
In Re Application Of: DABRE et al.							
Application No.		Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/509,824		3 April 2003	TBA	26815	ТВА	4355	
Title:	TASTE MA	SKED COMPOSITIO	ONS OF ERYTHROMYCIN A	AND DERIVAT	TIVES THEREO	F	
Address to:  Commissioner for Patents  P.O. Box 1450  Alexandria, VA 22313-1450							
			37 CFR 1.97(b)				
1. A The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)							
2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:							
☐ the statement specified in 37 CFR 1.97(e);							
OR							
	☐ the	fee set forth in 37 CF	·R 1.17(ρ).				

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 d 1.97(b) or 1.97(c)) **RLL-254US** In Re Application: DABRE et al. Confirmation No. Application No. Filing Date Examiner Customer No. Group Art Unit 10/509,824 **TBA** 26815 4355 3 April 2003 **TBA** Title: TASTE MASKED COMPOSITIONS OF ERYTHROMYCIN A AND DERIVATIVES THEREOF Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. ☑ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below. Charge the amount of Credit any overpayment. Charge any additional fee required. X ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Transmission by Facsimile\* Certificate of Mailing by First Class Mail I hereby certify that this correspondence is being deposited I certify that this document and authorization to charge deposit with the United States Postal Service with sufficient postage account is being facsimile transmitted to the United States as first class mail in an envelope addressed to Patent and Trademark Office (Fax. No. "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on (Date) (Date) Signature of Person Mailing Correspondence Signature Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate \*This certificate may only be used if paying by deposit account. Dated: 25 May 2005 William D. Hare, Reg. No. 44,739 Ranbaxy Inc. 600 College Road East, Suite 2100 Princeton, NJ 08540 Tel.: (609) 720-5378 Fax: (609) 514-9779 CC:

<b>INFORMATION</b>	DISCLOSU	<b>CITATION</b>

Docket No.: RLL-254US

Serial No.: 10/509,824

Applicants: DAB

t al.

Filed: 9/30/2004

Group:

			U.S. P	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,808,411	2/28/1989	Lu <i>et al</i> .	424	441	
	A2	5,919,489	7/6/1999	Saleki-Gerhardt et al.	424	501	
		,					
	·	`	FOREIGN	I PATENT DOCUMENTS	)		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO
	B1	WO 98/56357	12/17/1998	PCT	A61K	9/20	
	B2	WO 02/17885	3/7/2002	PCT	A61K	9/20	
	В3	EP 0 635 261	3/31/1999	EPO	A61K	9/16	
							I
		OTHER DOCUME	NTS (Includ	ding Author, Title, Date, P	ertinent P	ages, Etc.)	
	C1	Chemical Abstract of JP 2003104912 (XP002255954)					
	<u> </u>	<u></u>					

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.